Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER

Published November 1, 2018

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Published January 13, 2021

Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]

Published June 1, 2018

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University